Evidence map›Paper›PMID 39170882›Full record

ArticleOncology letters2024

Periprostatic adipose tissue inhibits tumor progression by secreting apoptotic factors: A natural barrier induced by the immune response during the early stages of prostate cancer.

I-Hung Shao, Tzu-Hsuan Chang, Ying-Hsu Chang, Yu-Hsin Hsieh, Ting-Wen Sheng, Li-Jen Wang, Yu-Hsuan Chien, Liang-Kang Huang, Yuan-Cheng Chu, Hung-Cheng Kan and 7 more

Abstract read
In one paragraph

Article in Oncology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

I-Hung ShaoDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Tzu-Hsuan ChangDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Ying-Hsu ChangSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan, R.O.C.
Yu-Hsin HsiehDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Ting-Wen ShengDepartment of Medical Imaging and Intervention, New Taipei Municipal Tucheng Hospital, New Taipei 236017, Taiwan, R.O.C.
Li-Jen WangDepartment of Medical Imaging and Intervention, New Taipei Municipal Tucheng Hospital, New Taipei 236017, Taiwan, R.O.C.
Yu-Hsuan ChienDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Liang-Kang HuangDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Yuan-Cheng ChuDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Hung-Cheng KanDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Po-Hung LinDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Kai-Jie YuDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Ming-Li HsiehDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Cheng-Keng ChuangDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Chun-Te WuDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
Chin-Hsuan HsiehDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.
See-Tong PangDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan, R.O.C.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is the second most prevalent malignancy in men worldwide. The risk factors for PCa include obesity, age and family history. Increased visceral fat has been associated with high PCa risk, which has prompted previous researchers to investigate the influence of body composition and fat distribution on PCa prognosis. However, there is a lack of studies focusing on the mechanisms and interactions between periprostatic adipose tissue (PPAT) and PCa cells. The present study investigated the association between the composition of pelvic adipose tissue and PCa aggressiveness to understand the role played by this tissue in PCa progression. Moreover, PPAT-conditioned medium (CM) was prepared to assess the influence of the PPAT secretome on the pathophysiology of PCa. The present study included 50 patients with localized PCa who received robot-assisted radical prostatectomy. Medical records were collected, magnetic resonance imaging scans were analyzed and body compositions were calculated to identify the associations between adipose tissue volume and clinical PCa aggressiveness. In addition, CM was prepared from PPAT and perivesical adipose tissue (PVAT) collected from 25 patients during surgery, and its effects on the PCa cell lines C4-2 and LNCaP, and the prostate epithelial cell line PZ-HPV-7, were investigated using a cell proliferation assay and RNA sequencing (RNA-seq). The results revealed that the initial prostate-specific antigen level was significantly correlated with pelvic and periprostatic adipose tissue volumes. In addition, PPAT volume was significantly higher in patients with extracapsular tumor extension. PCa cell proliferation was significantly reduced when the cells were cultured in PPAT-CM compared with when they were cultured in control- and PVAT-CM. RNA-seq revealed that immune responses, and the cell death and apoptosis pathways were enriched in PPAT-CM-cultured cells indicating that the cytokines or other factors secreted from PPAT-CM induced PCa cell apoptosis. These findings revealed that the PPAT secretome may inhibit PCa cell proliferation by activating immune responses and promoting cancer cell apoptosis. This mechanism may act as a first-line defense during the early stages of PCa.

Indexed as

clinicalflow cytometryGene Set Enrichment Analysismagnetic resonance imagingprostate cancer

Identifiers

PMID39170882
PMCPMC11338243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.